Arrowhead price target lowered to $55 from $59 at B. Riley

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Pharmaceuticals to $55 from $59 and keeps a Buy rating on the shares. The analyst says the company’s pipeline disclosures were not as worse as feared.